Pioneering Pain-free Solutions
We leverage the power of technology to develop transformative, accurate solutions that improve quality of life.
We're on a mission to redefine the approach to testing and deliver pain-free, accessible solutions that drive transformative change and improve the quality of life.
Our Technology
Revolutionizing Portable Drug Screening Through Fingertip Sweat Analysis
Our cutting-edge Intelligent Fingerprinting Drug Testing Solution detects commonly abused drugs via the fingertips. The system’s ease of use and portability make it a convenient solution for reliable drug screening and potential misuse within the 16 hours before testing.
INTELLIGENT DRUG SCREENING
A Dignified Approach to Drug Screening
Our Intelligent Drug Screening system tests fingertip sweat for recent drug use, including cannabis, cocaine, opiates, and methamphetamine. Samples are collected in less than one minute and results displayed in less than ten minutes.
THE BIOSENSOR PLATFORM
A Platform for Multiple Diagnostic Tests
The biosensor platform is a small, printable organic strip designed to put the power of accurate, timely diagnosis in the hands of patients and their primary health practitioners.
News Updates
INBS PK Study Results Video
The data from our pharmacokinetic (PK) study shows that fingerprint sweat mimics the rate and extent of codeine in blood and saliva. The study demonstrated that fingerprint sweat provides a
Intelligent Bio Solutions Announces Positive Results of PK Study, a Key Milestone on Path to FDA 510(k) Submission
PK Study Successfully Demonstrates that Fingerprint Sweat Provides Reliable Sample for Drug Detection FDA 510(k) Clearance Would Enable the Introduction of INBS’ Technology to the US in 2025 NEW YORK,
Intelligent Bio Solutions Reports Fiscal 2025 First Quarter Financial Results and Operational Highlights
Quarterly revenue increased 10% year-on-year and 20% quarter-on-quarter, marking four consecutive quarters of year-on-year growth Higher-margin, recurring cartridge revenue surpassed reader revenue as primary driver Completed in-clinic portion of FDA